Published in J Urol on April 12, 2012
Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol (2013) 1.06
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol (2012) 0.93
OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology (2013) 0.92
Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol (2014) 0.91
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection. Toxins (Basel) (2015) 0.91
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med (2013) 0.89
Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics (2014) 0.88
What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU? Cent European J Urol (2014) 0.86
Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity. J Exerc Rehabil (2016) 0.81
Current and potential urological applications of botulinum toxin A. Nat Rev Urol (2015) 0.80
Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life Questionnaire and Neurogenic Module. Health Qual Life Outcomes (2014) 0.79
Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl) (2015) 0.79
Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment. Spinal Cord (2016) 0.78
Autonomic Dysregulation in Multiple Sclerosis. Int J Mol Sci (2015) 0.78
Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective. Pharmacoeconomics (2015) 0.78
Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol (2016) 0.78
Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment. Korean J Urol (2014) 0.78
Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol (2016) 0.77
Emerging treatments for overactive bladder: clinical potential of botulinum toxins. Res Rep Urol (2014) 0.77
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. Int Braz J Urol (2015) 0.77
Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy. Int Neurourol J (2016) 0.77
Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis. Can Urol Assoc J (2014) 0.75
Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. Int Neurourol J (2017) 0.75
Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials. Health Qual Life Outcomes (2015) 0.75
The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol (2013) 0.75
Bladder management in individuals with chronic neurogenic lower urinary tract dysfunction. Spinal Cord (2015) 0.75
Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's disease. BMC Urol (2016) 0.75
Use of onabotulinumtoxinA for overactive bladder with concomitant warfarin. Consult Pharm (2014) 0.75
Botulinum toxin injections for treating neurogenic detrusor overactivity. Turk J Urol (2015) 0.75
Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder. Toxins (Basel) (2016) 0.75
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins (Basel) (2016) 0.75
Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2016) 0.75
Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep (2016) 0.75
How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? World J Nephrol (2016) 0.75
Botulinum toxin A for the Treatment of Overactive Bladder. Toxins (Basel) (2016) 0.75
Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms. Investig Clin Urol (2016) 0.75
Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport(®)) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? Toxins (Basel) (2015) 0.75
[Neurogenic detrusor overactivity - botulinum toxin type A injections improve quality of life]. Aktuelle Urol (2013) 0.75
Botulinum Toxin Treatment in Multiple Sclerosis-a Review. Curr Treat Options Neurol (2017) 0.75
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. Urol Clin North Am (2017) 0.75
Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. Curr Urol Rep (2017) 0.75
Use of botulinum toxin for voiding dysfunction. Transl Androl Urol (2017) 0.75
Follow-up urodynamics in patients with neurogenic bladder. Indian J Urol (2017) 0.75
Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity. World J Urol (2015) 0.75
Epidural Spinal Stimulation to Improve Bladder, Bowel, and Sexual Function in Individuals With Spinal Cord Injuries: A Framework for Clinical Research. IEEE Trans Biomed Eng (2017) 0.75
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 4.37
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol (2005) 2.68
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol (2011) 2.37
Task-shifting HIV counselling and testing services in Zambia: the role of lay counsellors. Hum Resour Health (2009) 2.02
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 1.92
Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Public Health (2009) 1.75
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol (2012) 1.61
The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med (2008) 1.56
Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn (2010) 1.55
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill (2016) 1.46
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol (2012) 1.46
Gastrointestinal tolerance of a new infant milk formula in healthy babies: an international study conducted in 17 countries. Nutrition (2002) 1.43
Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC Health Serv Res (2010) 1.42
Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42
Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue. Eur Urol (2007) 1.41
Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41
Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int (2012) 1.41
OnabotulinumtoxinA treatment of mild glabellar lines in repose. Dermatol Surg (2010) 1.40
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol (2007) 1.40
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31
Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS One (2011) 1.31
Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol (2006) 1.30
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol (2007) 1.27
Cardiovascular disease event classification in the Jackson Heart Study: methods and procedures. Ethn Dis (2005) 1.25
The spectra of clinical phenotypes in aplasia cutis congenita and terminal transverse limb defects. Am J Med Genet A (2009) 1.24
Clinical and molecular genetic features of Beckwith-Wiedemann syndrome associated with assisted reproductive technologies. Hum Reprod (2008) 1.23
Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol (2013) 1.18
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill (2015) 1.17
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol (2008) 1.16
Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord (2010) 1.15
Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol (2008) 1.13
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
From project aid to sustainable HIV services: a case study from Zambia. J Int AIDS Soc (2010) 1.10
Nicorandil-induced penile ulcerations: a case series. BJU Int (2011) 1.08
Animal models of female stress urinary incontinence. J Urol (2008) 1.08
Urethrovaginal fistula--a rare complication after the placement of a suburethral sling (IVS). Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.07
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn (2011) 1.06
Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Ann Neurol (2002) 1.06
Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex. Hum Mutat (2012) 1.05
Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol (2010) 1.05
In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann N Y Acad Sci (2009) 1.02
Will we ever use stem cells for the treatment of SUI? ICI-RS 2011. Neurourol Urodyn (2012) 1.02
Investigations of urothelial cells seeded on commercially available small intestine submucosa. Eur Urol (2006) 1.01
Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011. Emerg Infect Dis (2012) 1.01
Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach. Int J Urol (2009) 1.00
Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol (2007) 1.00
A newly designed amplatz sheath decreases intrapelvic irrigation pressure during mini-percutaneous nephrolitholapaxy: an in-vitro pressure-measurement and microscopic study. J Endourol (2007) 1.00
Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol (2012) 0.99
Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn (2012) 0.99
Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS One (2011) 0.99
Establishing a reference range for penile length in Caucasian British men: a prospective study of 609 men. BJU Int (2011) 0.99
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther (2007) 0.98
High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int (2011) 0.98
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. Euro Surveill (2016) 0.97
Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci (2013) 0.94
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology (2013) 0.93
Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia. Mov Disord (2010) 0.93
Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol (2011) 0.93
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol (2012) 0.93
Laser fragmentation of foreign bodies in the urinary tract: an in vitro study and clinical application. World J Urol (2009) 0.92
Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex. Hum Mutat (2012) 0.92
Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil (2006) 0.92
How does sacral modulation work best? Placement and programming techniques to maximize efficacy. Curr Urol Rep (2011) 0.92
Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis. World J Urol (2008) 0.92
OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology (2013) 0.92
The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol (2007) 0.91
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol (2011) 0.91
Corticospinal excitability accompanying ballistic wrist movements in primary dystonia. Mov Disord (2004) 0.91
WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of the cardiac and diaphragmatic malformations. Am J Med Genet A (2007) 0.91
Management of lower-pole stones of 0.8 to 1.5 cm maximal diameter by the minimally invasive percutaneous approach. J Endourol (2008) 0.91
The 12q14 microdeletion syndrome: six new cases confirming the role of HMGA2 in growth. Eur J Hum Genet (2011) 0.90
Can medical students from two cultures learn effectively from a shared web-based learning environment? Med Educ (2007) 0.90
Size does matter: 1.5 Fr. stone baskets almost double irrigation flow during flexible ureteroscopy compared to 1.9 Fr. stone baskets. Urol Res (2006) 0.89